Pfizer made over $50billion in 2023, versus $0.5billion for Telix during the same year. Clarity is pre-revenue.
Here below are the charts for the last 24 months: Clarity was far ahead of Pfizer in SP appreciation. Telix did better than Pfizer too.
I don't think people only just realised that Clarity is pre-revenue! There are other reasons for the selling. Profit taking? Perhaps!
-----
EXHIBIT B: Look closely at the Telix chart
See the drop from $8.70 to $3.60? There have been many other big big drops like it. It happens to the best!
Yet, even with those, the long term Telix chart remains a beauty!
IN CONCLUSION: Pre-revenue status alone does not cause a share price to dip. A lot of speculative biotech investors will specifically target pre-revenue companies in order to stay (and camp) ahead of the curve! The idea is to be there when the company turns a corner and declares profit (or indeed, when other catalytic events happen: FDA approval, Buy Outs, etc)!
Regards and Good Luck to you ALL! Long Term Investors and Short Term Traders alike.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)